The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
May 17, 2010
|
3 min read
The U.S. Food and Drug Administration (
April 15, 2010
|
1 min read
March 19, 2010
|
1 min read
The U.S. Food and Drug Administration approved an important new inhaled
Feb. 22, 2010
|
3 min read